In a randomized, double-blind trial, no benefit in visual acuity was found after 30 days, and serious bleeding events were recorded in the treatment group.
Acute central retinal artery occlusion (CRAO) is sometimes called “the stroke of the eye.” Blood flow to the retina is suddenly disrupted, and the damage can become irreversible within a short time. Because of the similarity to a stroke, the idea of using clot-dissolving drugs is occasionally raised. However, a randomized clinical trial called TenCRAOS, published on January 29, 2026 in the New England Journal of Medicine and summarized in PubMed, found that intravenous treatment with Tenecteplase did not significantly improve vision, and serious bleeding events were also recorded.
How the experiment was designed and what was tested
The trial was randomized, double-blind, and placebo-controlled. It included 78 patients diagnosed with central retinal artery occlusion and presented for treatment within a short window of symptom onset (a few hours). Participants were divided into two groups:
- A group that received intravenous infusion of tenactaplase.
- A group that received a placebo.
To maintain double-blindness, a concomitant medication was also given so that the treatment appeared to be the same in both groups. The primary study endpoint was a defined improvement in visual acuity after 30 days.
The scientific rationale is clear: If the blockage is caused by a clot, a clot dissolver may restore blood flow. But the eye has severe limitations: the retina is very time-sensitive, and sometimes the blockage is caused by a wandering clot (embolism) and sometimes by a sclerotic process. Therefore, it is not always clear that the drug “arrives in time,” that the blockage can indeed be dissolved, and that the window of rescue is still open. Because of this, a randomized trial is the right way to test whether there is a real benefit.
Results: No visual advantage, yes a safety signal
According to the PubMed abstract, the proportion of patients achieving the pre-specified visual improvement was similar between groups:
- 20% in the Tenctplaz group
- 24% in the control group
In other words, no benefit was found for the treatment. At the same time, a worrying safety signal emerged: one fatal intracranial hemorrhage was reported in the tenecteplase group, as well as more symptomatic intracranial hemorrhages in the treatment group compared to the control. Even if the numbers are small, when there is no clear evidentiary benefit, such events change the risk-benefit ratio to the detriment of the treatment.
What is the clinical significance and what next?
The practical conclusion from these data is simple: in the format tested in the TenCRAOS trial, tenketaflaz did not provide a clear clinical advantage in central retinal artery occlusion, and the risk of bleeding requires great caution. Furthermore, CRAO is sometimes a “warning light” for a vulnerable vascular system. Therefore, it is important to quickly identify risk factors (e.g., embolic source from the heart or carotid arteries) and to strengthen secondary prevention of stroke.
The results do not close the door to future research, but they raise the bar of proof: If other time windows, subgroups, or more targeted approaches are tested in the future, clear benefit versus real risk will need to be shown. Above all, the trial highlights a basic rule of evidence-based medicine: When a treatment has the potential to cause serious harm, biological logic is not enough—it requires proven clinical benefit.
Note: This is a scientific summary of research, not personal medical advice.
More of the topic in Hayadan:
